Latest Breaking News On - Michaelg palfreyman - Page 1 : comparemela.com

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results

Cybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMichaelg palfreymanAlex kelmanGabriel fahelAaron bartloneAlex belserTina muellerMagdyl shenoudaJoan krakowskyErik stangSebastian krempienMichaele morganKen averyKimball johnsonAlex nivorozhkin

Cybin Announces Poster Presentation at Neuroscience 2023 Annual Meeting

TORONTO, November 15, 2023 Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced a poster presentation at Neuroscience 2023 hosted by the Society for Neuroscience ("SFN") taking place November 11-15, 2022, in Washington, D.C.

United statesUnited kingdomClintone canalMichaele morganPradip pathareRicha tyagiErik stangJoshuaa hartselGabriel fahelGeoff vartyGeoffreyb vartyAmyc reicheltAlex nivorozhkinKen averyTinaa muellerMichaelg palfreyman

Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit

TORONTO - Cybin Inc. , a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today.

United statesUnited kingdomDoug drysdaleLynn marie morskiJoshuaa hartselErik stangAlex nivorozhkinGeoffreyb vartyKen averyGeoff vartyClintone canalMichael palfreymanTinaa muellerMichaelg palfreymanGabriel fahelMichaele morgan

Cybin to Present an Abstract and Moderate a Psychedelic Workshop at the 6th Annual Neuropsychiatric Drug Development Summit

- Abstract entitled, “Structure-activity of 2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with therapeutic potential” - - Highlights preclinical work done to support.

United statesUnited kingdomErik stangGeoff vartyLynn marie morskiClintone canalMichaele morganMichael palfreymanGeoffreyb vartyAlex nivorozhkinDoug drysdaleKen averyJoshuaa hartselTinaa muellerMichaelg palfreymanExchange commission

CYBIN Closes Acquisition of Adelia Therapeutics; Bolsters Scientific Team and Grows IP Portfolio to 7 Patent Filings

Adelia”) for up to CDN$20,161,575 (approximately USD$15.75 million) (the “ Transaction”). Transaction Highlights Newly acquired novel psychedelic molecules diversify Cybin’s development portfolio, providing access to multiple future indications. Selective modification, through deuteration of psychedelic parent molecules, allows control of the duration of action of these new chemical entities, enabling the design of both short and long-acting treatments. Adelia brings a range of technologies related to novel therapeutics, delivery methods, and therapeutic regimens, as well as six patent applications. Adelia contributes an expanding library of psychedelic derivative drug development candidates. The first lead compounds are expected to enter clinical studies in 2021, subject to receipt of approvals.

United statesNortheastern universityBrett greeneMichaelg palfreymanMichael palfreymanDoug drysdaleAlex nivorozhkinEli lillyBrettj greeneDevelopment officerCybin corpNova capital internationalCybin incDrug administrationCybin us holdings incHealth canada